Effects of growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trial.

ABSTRACT:

Objective

Recombinant human growth hormone (GH) and pioglitazone (PIO) in abdominally obese adults with impaired glucose tolerance were evaluated under the hypothesis that the combination attenuates GH-induced increases in glucose concentrations, reduces visceral adipose tissue (VAT), and improves insulin sensitivity over time.

Design

Randomized, double-blind, placebo-controlled, 2 x 2 factorial design.

Setting

Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States.

Participants

62 abdominally obese adults aged 40-75 with impaired glucose tolerance.

Interventions

GH (8 microg/kg/d, or placebo) and pioglitazone (30 mg/d, or placebo) for 40 wk.

Outcome measures

Baseline and after 40 wk of treatment, VAT content was quant

SUBMITTER: Attallah H 

PROVIDER: S-EPMC1865086 | biostudies-literature | 2007 May

REPOSITORIES: biostudies-literature